dc.contributor.author | Arslan, Serdal | |
dc.contributor.author | Pinarbasi, Hatice | |
dc.contributor.author | Silig, Yavuz | |
dc.date.accessioned | 2019-07-27T12:10:23Z | |
dc.date.accessioned | 2019-07-28T10:06:40Z | |
dc.date.available | 2019-07-27T12:10:23Z | |
dc.date.available | 2019-07-28T10:06:40Z | |
dc.date.issued | 2011 | |
dc.identifier.issn | 1791-2997 | |
dc.identifier.issn | 1791-3004 | |
dc.identifier.uri | https://dx.doi.org/10.3892/mmr.2010.378 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12418/9704 | |
dc.description | WOS: 000286301100015 | en_US |
dc.description | PubMed ID: 21461569 | en_US |
dc.description.abstract | Myeloperoxidase (M PO) is a phase I enzyme that can bioactivate many specific procarcinogens, including polycyclic aromatic hydrocarbons and aromatic amines. The MPO gene contains a common single nucleotide polymorphism, for which the -463G>A substitution within the promoter region has been shown to reduce MPO expression and activity. We investigated the association between the MPO -463G>A polymorphism and lung and prostate cancer in a Turkish population. MPO genotypes in the study populations were determined using polymerase chain reaction-based restriction fragment length polymorphism assay. The allelic frequency was significantly different between the cases and controls for lung cancer (p=0.02), but not prostate cancer (p=0.30). No significant difference was noted between the lung and prostate cancer cases and control populations in terms of genotype distribution (p=0.07, p=0.53, respectively). Control groups of lung and prostate cancer were in Hardy-Weinberg equilibrium (p=0.87 and p=0.41, respectively). To determine the protective effect against lung cancer among individuals with the -463A allele, C/A and A/A genotypes were combined. Comparison of the GIG and C/A + A/A genotypes between the lung cancer cases and control groups showed a statistically significant relationship (p=0.032, OR=0.60, 95% CI 0.38-0.95). No gender-specific difference was found in terms of genotype distribution between the lung cancer patients and the controls (female, p=0.20; male, p=0.34). In the case of smokers, a difference in genotype distribution between the lung cancer patients and the controls was statistically significant (p=0.02), although this difference was not statistically significant for non-smokers (p=0.90). Overall, no statistically significant difference was found between the prostate cancer cases and the controls in terms of genotype combination (p=0.46, OR=0.83, 95% CI 0.51-1.36). Additionally, in smokers and non-smokers, no significant relationship was determined between the prostate cancer patients and the control population (p=0.21, p=0.91, respectively). These results suggest that the MPO -463A allele significantly contributes to a protective effect overall and in smokers against lung cancer. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | SPANDIDOS PUBL LTD | en_US |
dc.relation.isversionof | 10.3892/mmr.2010.378 | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | lung cancer | en_US |
dc.subject | prostate cancer | en_US |
dc.subject | myeloperoxidase | en_US |
dc.subject | polymorphism | en_US |
dc.subject | Turkish population | en_US |
dc.title | Myeloperoxidase G-463A polymorphism and risk of lung and prostate cancer in a Turkish population | en_US |
dc.type | article | en_US |
dc.relation.journal | MOLECULAR MEDICINE REPORTS | en_US |
dc.contributor.department | [Pinarbasi, Hatice -- Silig, Yavuz] Cumhuriyet Univ, Dept Biochem, Fac Med, TR-58140 Sivas, Turkey -- [Arslan, Serdal] Cumhuriyet Univ, Fac Sci, Dept Mol Biol & Genet, TR-58140 Sivas, Turkey | en_US |
dc.identifier.volume | 4 | en_US |
dc.identifier.issue | 1 | en_US |
dc.identifier.endpage | 92 | en_US |
dc.identifier.startpage | 87 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |